ASCE - ETF AI Analysis
Top Page
Allspring SMID Core ETF (ASCE)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Year-to-Date Results
The ETF has delivered strong gains so far this year, suggesting its strategy has recently worked well for investors.
Multiple Sectors Represented
Holdings spread across technology, financials, health care, consumer cyclical, and other sectors help reduce the impact of weakness in any single industry.
Several Strong-Performing Top Holdings
Many of the largest positions, such as Blue Bird, Corcept Therapeutics, and others, have shown strong performance, supporting the fund’s overall returns.
Negative Factors
High U.S. Concentration
Almost all assets are invested in U.S. companies, offering little geographic diversification if the U.S. market faces a downturn.
Mixed Short-Term Performance
The ETF has recently experienced a weak one-month stretch, showing that returns can be bumpy over shorter periods.
Moderate Expense Ratio
The fund’s fees are not especially low, which means costs could eat into returns compared with cheaper ETFs.
ASCE vs. SPDR S&P 500 ETF (SPY)
AUM162.98M
RegionNorth America
Expense Ratio0.38%
Beta1.06
IssuerAllspring
Inception DateJul 08, 2025
Dividend Yield0.17%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume157,867
30 Day Avg. Volume61,797
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
40.74Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ASCE Summary
The Allspring SMID Core ETF (ASCE) invests in a wide mix of smaller and mid-sized U.S. companies, aiming for long-term growth by focusing on the “extended market” beyond the biggest household-name stocks. It doesn’t track a set index, but instead selects individual stocks across many sectors, including health care, technology, and financials. Well-known holdings include Blue Bird and Exelixis. Investors might consider ASCE to diversify beyond large caps and tap into the growth potential of smaller, up-and-coming businesses. A key risk is that smaller-company stocks can be more volatile and may rise or fall faster than the overall market.
How much will it cost me?The Allspring SMID Core ETF (ASCE) has an expense ratio of 0.38%, meaning you’ll pay $3.80 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it is actively managed, focusing on identifying undervalued opportunities in small to mid-cap stocks. Active management typically involves more research and decision-making, which can increase expenses.
What would affect this ETF?The Allspring SMID Core ETF could benefit from growth in the U.S. economy, particularly in sectors like technology and healthcare, which are among its top exposures. However, it may face challenges if interest rates rise, as smaller companies often have higher borrowing costs, or if economic uncertainty impacts consumer spending and industrial activity. Its focus on undervalued small to mid-cap stocks provides opportunities for growth but also exposes it to higher volatility compared to large-cap investments.
ASCE Top 10 Holdings
ASCE leans heavily into U.S. small and mid-cap names, with health care and industrials quietly steering the ship. Corcept Therapeutics and Exelixis have been rising, giving the fund a solid lift from the biotech corner, while Amneal Pharmaceuticals adds steady, if less explosive, support. On the industrial side, Carpenter Technology has been a standout, helping offset mixed trading in Blue Bird, where momentum has cooled. TTM Technologies, despite a recent lag, still reflects the fund’s tilt toward niche tech, making ASCE a domestically focused, diversified bet on under-the-radar growth stories.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Corcept Therapeutics | 3.77% | $5.95M | $12.38B | 57.17% | 76 Outperform | |
| Amneal Pharmaceuticals | 2.95% | $4.65M | $5.85B | 136.81% | 58 Neutral | |
| Blue Bird | 2.82% | $4.45M | $2.35B | 68.89% | 69 Neutral | |
| Acadian Asset Management | 2.81% | $4.44M | $3.08B | 121.02% | 66 Neutral | |
| Virtu Financial | 2.50% | $3.93M | $9.11B | 35.61% | 64 Neutral | |
| Exelixis | 2.47% | $3.90M | $13.33B | 49.58% | 78 Outperform | |
| SkyWest | 2.45% | $3.86M | $4.15B | 1.54% | 74 Outperform | |
| SharkNinja, Inc. | 2.37% | $3.74M | $22.89B | 38.10% | 76 Outperform | |
| Chord Energy | 2.35% | $3.71M | $7.90B | 32.23% | 76 Outperform | |
| Universal Health | 2.34% | $3.68M | $10.19B | 2.65% | 74 Outperform |
ASCE Technical Analysis
Positive
―
Price Trends
33.93
Positive
31.92
Positive
29.64
Positive
Market Momentum
0.15
Negative
61.75
Neutral
87.89
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ASCE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 34.04, equal to the 50-day MA of 33.93, and equal to the 200-day MA of 29.64, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 61.75 is Neutral, neither overbought nor oversold. The STOCH value of 87.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASCE.
ASCE Peer Comparison
Comparison Results
Performance Comparison
ASCE
Allspring SMID Core ETF
35.25
10.54
42.65%
RSMC
Rockefeller U.S. Small-Mid Cap ETF
―
―
―
MSSM
Morgan Stanley Pathway Small-Mid Cap Equity ETF
―
―
―
GRNJ
Fundstrat Granny Shots US Small- & Mid-Cap ETF
―
―
―
SMIZ
Zacks Small/Mid Cap ETF
―
―
―
RNIN
Bushido Capital US SMID Cap Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents